Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Climb Bio is set to announce its Q2 2025 earnings on August 13, with expected earnings of ($0.19) per share.
• The company's last reported earnings were ($0.31) per share, missing analysts' expectations by ($0.16).
• Equities analysts have given Climb Bio a "buy" rating and an "outperform" rating with a price target of $10.00.

Climb Bio (NASDAQ:CLYM - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.16). On average, analysts expect Climb Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Climb Bio Trading Up 1.2%

Shares of CLYM traded up $0.02 during midday trading on Friday, reaching $1.70. 260,047 shares of the company were exchanged, compared to its average volume of 500,054. The stock has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.37. The company has a market cap of $114.89 million, a price-to-earnings ratio of -0.71 and a beta of -0.11. Climb Bio has a 1-year low of $1.05 and a 1-year high of $8.79.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Climb Bio stock. Goldman Sachs Group Inc. purchased a new position in Climb Bio, Inc. (NASDAQ:CLYM - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 120,742 shares of the company's stock, valued at approximately $147,000. Goldman Sachs Group Inc. owned approximately 0.18% of Climb Bio as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 69.76% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CLYM shares. BTIG Research started coverage on Climb Bio in a research note on Thursday, May 22nd. They set a "buy" rating on the stock. Oppenheimer initiated coverage on Climb Bio in a research note on Friday, June 6th. They issued an "outperform" rating and a $10.00 price target on the stock.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.